Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn’s disease

✍ Scribed by Paul Rutgeerts; Stefan Schreiber; Brian Feagan; Dorothy L. Keininger; Liz O’Neil; Richard N. Fedorak; CDP870 Crohn’s Disease Study Group

• Publisher: Springer
• Year: 2007
• Tongue: English
• Weight: 250 KB
• Volume: 23
• Category: Article
• ISSN: 0179-1958
• DOI: 10.1007/s00384-007-0395-7